retifanlimab
retifanlimab: sourced relationships with 1 company · 35 clinical trials tracked · 1 FDA decision.
retifanlimab evidence translation
What we can confirm
1 FDA record · 35 tracked trials
What it means
What to watch
Prepared research question
How could retifanlimab → INCY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 2 study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Incyte Corp. (INCY) Reported 2023-03-22 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (35)showing 10 most recent
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC)
A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)
Primary endpoint: Objective response rate (ORR)
ctHPVDNA Adapted ChemoRadiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer (CHART-AC)
Primary endpoint: 1-year Disease-free survival (DFS) by response subgroup
PRISM: Phase 1b of Retifanlimab and Ruxolitinib In Solid Malignancies Progressing on Prior Checkpoint Inhibition
Primary endpoint: Recommended phase 2 dose
A Phase Ib Study of 9-ING-41 (Elraglusib), a Glycogen Synthase Kinase 3-beta (GSK-3β) Inhibitor, Combined With Retifanlimab, a PD-1 Inhibitor, Plus Modified FOLFIRINOX as Frontline Therapy for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
Primary endpoint: Dose Limiting Toxicities (DLTs)
A Phase 1/2, Open-Label, Multicenter Study of INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)
A Trial to Evaluate Deoxyribonucleic) in BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B1)-Altered Glioma During Treatment With Plixorafenib Alone or With Retifanlimab
Primary endpoint: Detection rate of BRAF-V600E ctDNA in CSF and/or plasma
A Phase Ib/II Study of Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced Solid Tumors
Primary endpoint: Incidence of dose limiting toxicities (phase Ib)
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)
Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Primary endpoint: Overall Survival
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with retifanlimab?
retifanlimab has dated SEC/FDA relationship records for Incyte Corp..
How many clinical trials involve retifanlimab?
BioSniper tracks 35 clinical trials involving retifanlimab.
What is retifanlimab's latest FDA decision?
The most recent tracked FDA decision for retifanlimab is Approval for 1 INDICATIONS AND USAGE ZYNYZ is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Squamous Cell Carcinoma of the Anal Canal (SCAC) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). ( 1.1 ) as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. ( 1.1 ) Merkel Cell Carcinoma (MCC) for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). ( 1.2 ) 1.1 Squamous Cell Carcinoma of the Anal Canal ZYNYZ, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). ZYNYZ, as a single agent, is indicated for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum‑based chemotherapy. 1.2 Merkel Cell Carcinoma ZYNYZ is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)., dated March 22, 2023.